Array Biopharma Inc.

Genentech, Inc.

Pfizer Corporation

Loxo Oncology, Inc.

Eli Lilly and Company

David A Moreno

Li Ren

James F Blake

Andrew T Metcalf

Adam Wade Cook

Gabrielle R Kolakowski

Tony P Tang

Yutong Jiang

Julia Haas

Steven Wade Andrews

Elizabeth A McFaddin

Megan L McKenney

Barbara J Brandhuber

Oren T McNulty

Sean Douglas Aronow

Shane M Walls

Huifen Chen

Jacob Bradley Schwarz

Peter J Mohr

Ginelle A Ramann

John Joseph Gaudino

Jonas Grina

Mark Joseph Chicarelli

Ellen Ruth Laird

Kevin W Hunt

Brad Newhouse

Indrani W Gunawardana

Rustam Ferdinand Garrey

James Collier

Brett Joseph Prigaro

Lewis J Gazzard

Kirk D Robarge

Aihe Zhou

Donghua Dai

Dean Russell Kahn

Erik James Hicken

Charles Todd Eary

Weidong Liu

Michael Lyon

Stacey Spencer

Mike Welch

Alex Andrew Kellum

Patrick Michael Doerner Barbour

Jane Schmidt

Zack Crane

Katelyn Chando

Sylvie Asselin

Alexandre Joseph Buckmelter

Shelley Allen

Bainian Feng

Wendy B Young

Mark Laurence Boys

Simon Mathieu

Janet Gunzner

Bradley Jon Newhouse

Joachim Rudolph

Allen A Thomas

Spencer Phillip Pajk

Zhaoyang Wen

Joshua Ryan Dahlke

Patrick Michael Barbour

Steven Mark Wenglowsky

Eugene Tarlton

Jacob Matthew O'Leary

Kateri Ahrendt

Katie Keaton Brown

Joshua D Hansen

Kim Malesky

Eli M Wallace

Jeongbeob Seo

Hongqi Tian

Samuel S Kintz

Robert J Kaus

Christopher Stephen Siedem

Jason De Meese

Elizabeth A Mcfaddin

Oren Teague Mcnulty

Jason Demeese

Connor James Cowdrey

Sydney Taylor Blanche

Wesley Dewitt Clark

Ellen Margaret Knapp

Jennifer Lynn Fulton

Faith Elizabeth Witkos

Tanna Marie Bettendorf

Megan L Mckenney

Hailong Zhang

Steve Do

Paul Lunghofer

Kateri A Ahrendt

Brett Prigaro

Dean Kahn

Oren T Mcknulty

Christopher S Siedem

Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I; and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Xis N and Ring A, Ring B, Ring C, X, X, R, L, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, such as e.g. cancer, e g. bladder cancer, brain cancer, breast cancer, cholangiocarcinoma, head and neck cancer, lung cancer, multiple myeloma, rhabdomyosarcoma, urethral cancer and uterine cancer. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 276 to 308; examples 1 to 30; examples A to E; tables CA to EE). An exemplary compound is e.g. 1-(3-(4-(4-(7-((3,5-dimethoxy phenyl) amino)quinoxalin-2-yl)-1H-pyrazol-1-yl)piperidine-1-carbonyl) azetidin-1-yl)prop-2-en-1-one (e.g. example 1).

Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases

Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Rand L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R, R, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R, R, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Fused heterocyclic compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X, X, Xand Xhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, Rand Rare as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors

Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein Rand Rhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors

Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R, Rand Rhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors

Growing community of inventors

Boulder, CO, United States of America

David A Moreno